NCT00945503View on ClinicalTrials.gov

Positron Emission Tomography (PET) Study to Describe the Relationship Between Plasma Concentrations and Brain Gly-T1 Occupancy of GSK1018921 Over Time.

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

May 19, 2008

Primary Completion Date

December 22, 2008

Study Completion Date

December 22, 2008

Conditions
Schizophrenia
Interventions
DRUG

GSK1018921

GSK1018921 is a GT1 recepor antagonist

Trial Locations (1)

Unknown

GSK Investigational Site, Barcelona

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00945503 - Positron Emission Tomography (PET) Study to Describe the Relationship Between Plasma Concentrations and Brain Gly-T1 Occupancy of GSK1018921 Over Time. | Biotech Hunter | Biotech Hunter